Kopran Limited

KOPRAN

INE082A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:14:56 2024-05-31 am EDT			5-day change	1st Jan Change
225.4 ^INR	+0.11%		-4.27%	-6.61%

May. 16	Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024	CI
May. 16	Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024

May 16, 2024 at 04:08 am EDT

Kopran Limited has recommended dividend of INR 3.00 per Equity Share of F.V INR 10 (30%) for the financial year ended March 31, 2024. The dividend recommended by the Board is subject To Approve the Members of the Company at the forthcoming 65th Annual General Meeting, scheduled to be held on September 11, 2024.

Latest news about Kopran Limited

Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024	May. 16	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 16	CI
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 07	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Kopran Limited Announces Renewal of Gmp Compliance Certificate by Medicines & Healthcare Products Regulatory Agency of United Kingdom (Mhra - Uk)	23-09-01	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Revises Outlook to Negative	23-08-17	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Kopran Limited Recommends Dividend for the Year Ended March 31, 2023	23-05-25	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
Crisil Keeps BBB+ Rating on Kopran's Bank Loans; Outlook Stable	23-04-26	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India	22-10-30	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Kopran Limited Recommends Dividend for the Financial Year 2021-2022	22-05-27	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-27	CI
Kopran Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-27	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Outlook Stable	22-05-20	MT
Kopran Invests Over $13 Million in Subsidiary	22-03-20	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-03	CI
Kopran Limited announced that it has received INR 1.264799745 billion in funding from Mahima STOCKS Private Limited, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited	22-01-11	CI
Pharmaceuticals Manufacturer Kopran's Arm Gets New Patent in India	21-12-12	MT
Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investors	21-12-07	CI
Kopran's Board to Consider Issuance of Equity Shares	21-12-03	MT
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-10-27	CI

Chart Kopran Limited

Duration

Period

More charts

Company Profile

Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOPRAN LIMITED	-6.61%	130M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B